NATCO Pharma Limited (NATCOPHARM.BO)
INR 771.25
(0.63%)
INR 771.25
(0.63%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 10.53 Billion INR | 34.41% |
| 2022 | 7.83 Billion INR | -7.32% |
| 2021 | 8.45 Billion INR | 26.48% |
| 2020 | 6.68 Billion INR | -16.76% |
| 2019 | 8.03 Billion INR | -1.11% |
| 2018 | 8.12 Billion INR | 27.07% |
| 2017 | 6.39 Billion INR | -3.78% |
| 2016 | 6.64 Billion INR | 27.46% |
| 2015 | 5.21 Billion INR | -2.16% |
| 2014 | 5.32 Billion INR | 15.04% |
| 2013 | 4.62 Billion INR | -13.68% |
| 2012 | 5.36 Billion INR | 24.53% |
| 2011 | 4.3 Billion INR | 21.72% |
| 2010 | 3.53 Billion INR | 45.23% |
| 2009 | 2.43 Billion INR | -6.28% |
| 2008 | 2.59 Billion INR | 33.78% |
| 2007 | 1.94 Billion INR | 18.65% |
| 2006 | 1.63 Billion INR | 6.27% |
| 2005 | 1.54 Billion INR | -11.31% |
| 2004 | 1.73 Billion INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | -58.53 Billion INR | -655.74% |
| 2023 FY | 10.53 Billion INR | 34.41% |
| 2023 Q4 | 10.53 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 9.6 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q4 | 7.83 Billion INR | 0.0% |
| 2022 FY | 7.83 Billion INR | -7.32% |
| 2022 Q2 | 5.06 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2021 FY | 8.45 Billion INR | 26.48% |
| 2021 Q2 | 8.23 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q4 | 8.45 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q4 | 6.68 Billion INR | 0.0% |
| 2020 FY | 6.68 Billion INR | -16.76% |
| 2020 Q2 | 10.26 Billion INR | 0.0% |
| 2019 FY | 8.03 Billion INR | -1.11% |
| 2019 Q2 | 7.73 Billion INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q4 | 8.03 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 Q4 | 8.12 Billion INR | 0.0% |
| 2018 Q2 | 8.68 Billion INR | 0.0% |
| 2018 FY | 8.12 Billion INR | 27.07% |
| 2018 Q3 | - INR | -100.0% |
| 2017 Q2 | 5.62 Billion INR | 0.0% |
| 2017 Q4 | 6.39 Billion INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q1 | - INR | -100.0% |
| 2017 FY | 6.39 Billion INR | -3.78% |
| 2016 Q2 | 6.65 Billion INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 FY | 6.64 Billion INR | 27.46% |
| 2016 Q4 | 6.64 Billion INR | 0.0% |
| 2015 Q2 | 4 Billion INR | 0.0% |
| 2015 FY | 5.21 Billion INR | -2.16% |
| 2015 Q1 | - INR | -100.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q4 | 5.21 Billion INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2014 Q2 | 4.98 Billion INR | 0.0% |
| 2014 FY | 5.32 Billion INR | 15.04% |
| 2014 Q4 | 5.32 Billion INR | 0.0% |
| 2014 Q3 | - INR | -100.0% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q4 | 4.62 Billion INR | 0.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 FY | 4.62 Billion INR | -13.68% |
| 2013 Q2 | 6.41 Billion INR | 0.0% |
| 2012 Q4 | 5.36 Billion INR | 0.0% |
| 2012 FY | 5.36 Billion INR | 24.53% |
| 2012 Q2 | 5.12 Billion INR | 0.0% |
| 2012 Q3 | - INR | -100.0% |
| 2011 Q4 | 4.3 Billion INR | 0.0% |
| 2011 FY | 4.3 Billion INR | 21.72% |
| 2010 FY | 3.53 Billion INR | 45.23% |
| 2009 FY | 2.43 Billion INR | -6.28% |
| 2008 FY | 2.59 Billion INR | 33.78% |
| 2007 FY | 1.94 Billion INR | 18.65% |
| 2006 FY | 1.63 Billion INR | 6.27% |
| 2005 FY | 1.54 Billion INR | -11.31% |
| 2004 FY | 1.73 Billion INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | 35.282% |
| Aurobindo Pharma Limited | 152.2 Billion INR | 93.08% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | -103.285% |
| Granules India Limited | 22.95 Billion INR | 54.118% |
| Indoco Remedies Limited | 10.34 Billion INR | -1.834% |
| Achyut Healthcare Limited | 2.01 Million INR | -523099.205% |
| Ajanta Pharma Limited | 10.71 Billion INR | 1.665% |
| Alkem Laboratories Limited | 48.6 Billion INR | 78.331% |
| Alpa Laboratories Limited | 307.12 Million INR | -3329.256% |
| Brooks Laboratories Limited | 248.6 Million INR | -4136.507% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | -187.672% |
| Bajaj HealthCare Limited | 4.86 Billion INR | -116.366% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | -399.419% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 90.154% |
| Eris Lifesciences Limited | 38.26 Billion INR | 72.478% |
| FDC Limited | 3.7 Billion INR | -183.942% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 83.824% |
| Gufic Biosciences Limited | 5.59 Billion INR | -88.078% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | -360.021% |
| Ipca Laboratories Limited | 33.74 Billion INR | 68.787% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -3448.996% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | -254.146% |
| Lasa Supergenerics Limited | 541.92 Million INR | -1843.442% |
| Laurus Labs Limited | 42.71 Billion INR | 75.343% |
| Lupin Limited | 96.23 Billion INR | 89.056% |
| Mankind Pharma Limited | 23.87 Billion INR | 55.886% |
| Medicamen Biotech Limited | 940.36 Million INR | -1019.988% |
| Medico Remedies Limited | 438.24 Million INR | -2303.227% |
| Megasoft Limited | 1.85 Billion INR | -468.332% |
| Piramal Pharma Limited | 74 Billion INR | 85.768% |
| RPG Life Sciences Limited | 1.38 Billion INR | -663.078% |
| Sigachi Industries Limited | 2.53 Billion INR | -316.077% |
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 94.263% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | -417.739% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | -803.871% |
| Unichem Laboratories Limited | 8.06 Billion INR | -30.52% |
| Wanbury Limited | 3.15 Billion INR | -233.765% |
| Windlas Biotech Limited | 1.76 Billion INR | -497.492% |
| ZIM Laboratories Limited | 2.08 Billion INR | -406.161% |
| Zydus Lifesciences Limited | 71.79 Billion INR | 85.33% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | -170.544% |
| Divi's Laboratories Limited | 18.99 Billion INR | 44.539% |
| Hester Biosciences Limited | 3.59 Billion INR | -192.985% |
| Procter & Gamble Health Limited | 2.56 Billion INR | -311.213% |
| Amrutanjan Health Care Limited | 783.82 Million INR | -1243.669% |
| Bal Pharma Limited | 2.51 Billion INR | -319.388% |
| Strides Pharma Science Limited | 37.68 Billion INR | 72.049% |
| Venus Remedies Limited | 1.39 Billion INR | -656.175% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | -27.65% |
| Nectar Lifesciences Limited | 11.21 Billion INR | 6.116% |
| Shilpa Medicare Limited | 12.93 Billion INR | 18.562% |
| Aarti Drugs Limited | 11.5 Billion INR | 8.449% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | -66.411% |
| Suven Life Sciences Limited | 148.62 Million INR | -6986.482% |
| Ind-Swift Limited | 13.45 Billion INR | 21.712% |
| Valiant Laboratories Limited | 1.05 Billion INR | -895.22% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | 1.644% |
| Solara Active Pharma Sciences Limited | 14.14 Billion INR | 25.536% |
| Themis Medicare Limited | 1.88 Billion INR | -457.984% |
| Hikal Limited | 12.99 Billion INR | 18.953% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | 87.164% |
| Sequent Scientific Limited | 8.27 Billion INR | -27.286% |
| Novartis India Limited | 1.8 Billion INR | -484.754% |
| Wockhardt Limited | 39.87 Billion INR | 73.584% |
| Jubilant Pharmova Limited | 61.27 Billion INR | 82.812% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -3546.827% |
| Neuland Laboratories Limited | 5.49 Billion INR | -91.541% |
| Morepen Laboratories Limited | 4.45 Billion INR | -136.155% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -1535.701% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | -432.912% |